In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation

British Journal of Pharmacology

Volumn 120, Issue 3, 1997, Pages 488-494

  Virone Oddos, A ^a   Desangle, V ^a   Provost, D ^a   Cazes, M ^a   Caussade, F ^a   Cloarec, A ^a  

^a UPSA Laboratories   (France)

Author keywords

125I Sar1 Ile8 binding; Angiotenisin II receptor; EXP 3174; Hyperplasia; Hypertensive rat VSMC model; Hypertrophy; Losartan; Neointimal proliferation; Normotensive rat VSMC model; UP 269 6; Vascular smooth muscle cells (VSMC)

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 5 METHYL 7 PROPYL 8 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 2(3H) ONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; LOSARTAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTERY INJURY; ARTICLE; CAROTID ARTERY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BALLOON DILATATION; BIPHENYL COMPOUNDS; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CELL DIVISION; IMIDAZOLES; LOSARTAN; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; PYRIMIDINES; RATS; RATS, INBRED SHR; RATS, WISTAR; RECEPTORS, ANGIOTENSIN; STIMULATION, CHEMICAL; TETRAZOLES;

EID: 0031036604     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0700897     Document Type: Article

References (35)

1. BERK, B.C., VEKSHTEIN, V., GORDON, H.M. & TSUDA, T. (1989). Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension, 13, 305-314.
2. BODIN, P., RICHARDS, S., TRAVO, C., BERTA, P., STOCLET, J.C., PAPIN, S. & TRAVO, P. (1991). Responses of subcultured rat aortic smooth muscle myocytes to vasoactive agents and KCl-induced depolarization. Am. J. Physiol., 260, C151-C158.
3. BUNKENBURG, B., VAN AMELSVOORT, T., ROGG, H. & WOOD, J.M. (1992). Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension, 20, 746-754.
4. CAUSSADE, F., VIRONE-ODDOS, A., DELCHAMBRE, C., CAZES, M., VERSIGNY, A. & CLOAREC, A. (1995). In vitro pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist. Fundam. Clin. Pharmacol., 9, 119-128.
5. CAZES, M., PROVOST, D., VERSIGNY, A. & CLOAREC, A. (1995). In vivo pharmacological characterization of UP269-6, a novel nonpeptide angiotensin II receptor antagonist. Eur. J. Pharmacol., 284, 157-170.
6. CHENG, Y.C. & PRUSOFF, W.H. (1973). Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol., 22, 3099-3108.
7. CHIU, A.T., MCCALL, D.E., PRICE, W.A., WONG, P.C., CARINI, D.J., DUNCIA, J.V., WEXLER, R.R., YOO, S.E., JOHNSON, A.L. & TIMMERMANS, P.B.M.W.M. (1990). Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther., 252, 711-718.
8. CLOWES, A.W., REIDY, M.A. & CLOWES, M.M. (1983a). Mechanisms of stenosis after arterial injury. Lab. Invest., 49, 208-215.
9. CLOWES, A.W., REIDY, M.A. & CLOWES, M.M. (1983b). Kinetics of cellular proliferation after injury, I: smooth muscle growth in the absence of endothelium. Lab. Invest., 49, 327-333.
10. DICKINSON, K.E.J., COHEN, R.B., SKWISH, S, DELANEY, C.L., SERAFINO, R.P., POSS, M.A., GU, Z., RYONO, D.E., MORELAND, S. & POWELL, J.R. (1994). BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174. Br. J. Pharmacol., 113, 179-189.
11. GABE M. (1968). Techniques Histologiques. ed. Masson & Cie, pp. 214-215, Paris.
12. GEISTERFER, A.A.T., PEACH, M.J. & OWENS, G.K. (1988), Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ. Res., 62, 749-756.
13. GOODFELLOW, B.S. & MIKAT, E.M. (1988). A stain for the simultaneous demonstration of collagen, muscle, and elastic elements in mammalian tissue. Lab. Med., 19, 243-244.
14. HADRAVA, V., TREMBLAY, J. & HAMET, P. (1989). Abnormalities in growth characteristics of aortic smooth muscle cells in spontaneously hypertensive rats. Hypertension, 13, 589-597.
15. HARRIS, E.L., GRIGOR, M.R. & MILLAR, J.A. (1990). Differences in mitogenic responses to angiotensin II, calf serum and phorbol ester in vascular smooth muscle cells from two strains of genetically hypertensive rat. Biochem. Biophys. Res. Commun., 170, 1249-1255.
16. IWAI, N., YAMANO, Y., CHAKI, S., KONISHI, F , BERDHAN, S., TIBBETS, C., SASAKI, K., HASEGAWA, M., MATSUDA, Y. & INAGAMI, T. (1991). Rat angiotensin II receptor: cDNA sequence and regulation of the gene expression. Biochem. Biophys. Res. Commun., 177, 299-304.
17. KAMBAYASHI, Y., BARDHAN, S. & INAGAMI, S. (1993). Peptide growth factors markedly decrease the ligand binding of angiotensin II type 2 receptor in rat cultured vascular smooth muscle cells. Biochem. Biophys. Res. Commun., 194, 478-482.
18. KAUFFMAN, R.F., BEAN, J.S., ZIMMERMAN, K.M., BROWN, R.F. & STEINBERG, M.I. (1991). Losartan, a nonpeptide angiotensin II (AngII) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. Life Sci., 49, PL-223-PL228.
19. KOH, E., MORIMOTO, S., TOMITA, J., RAKUGI, H , JIANG, B., INOUE, T., NABATA, T., FUKUO, K & OGIHARA, T. (1994). Effects of an angiotensin II receptor antagonist CV-11974, on angiotensin II-induced increases in cytosolic free calcium concentration, hyperplasia and hypertrophy of cultured vascular smooth muscle cells. J. Cardiovasc. Pharmacol., 23, 175-179.
20. McPHERSON, G.A. (1983). A practical computer-based approach to the analysis of radioligand binding experiments. Comput. Programs Biomed., 17, 107-114.
21. McPHERSON, G.A. (1985). Analysis of radioligand binding experiments: a collection of computer programs for the IBM PC. J. Pharmacol. Methods, 14, 213-228.
22. MILLET, D., DESGRANGES, C., CAMPAN, M., GADEAU, A-P. & COSTEROUSSE, O. (1992). Effects of angiotensins on cellular hypertrophy and c-fos expression in cultured arterial smooth muscle cells. Eur. J. Biochem., 206, 367-372.
23. MURPHY, T.J., ALEXANDER, R.W., GRIENDLING, K.K., RUNGE, M.S. & BERNSTEIN, K.E. (1991). Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature, 351, 233-236.
24. NICOLAÏ, E., CURE, G., GOYARD, J., KIRCHNER, M., TEULON, J.M., VERSIGNY, A., CAZES, M., CAUSSADE, F., VIRONE-ODDOS, A. & CLOAREC, A. (1994). Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists. J. Med. Chem., 37, 2371-2386.
25. OWENS, G.K. (1987). Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension, 9, 178-187.
26. PAQUET, J.L., BAUDOIN-LEGROS, M., BRUNELLE, G. & MEYER, P. (1990). Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J. Hypertens., 8, 565-572.
27. POWELL, J.S., CLOZEL, J.P., MÜLLER, R.K.M., KUHN, H., HEFTI, F., HOSANG, M. & BAUMGARTNER, H.R. (1989). Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science, 245, 186-188.
28. POWELL, J.S., MULLER, R.K.M., ROUGE, M., KUHN, H., HEFTI, F. & BAUMGARTNER, H.R. (1990). The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition. J. Cardiovasc. Pharmacol., 16, Suppl 4, S42-S49.
29. POWELL, J.S., MULLER, R.K.M. & BAUMGARTNER, H.R. (1991). Suppression of the vascular response to injury: the role of angiotensin-converting enzyme inhibitors. J. Am. Coll. Cardiol., 17, 137B-142B.
30. PRESCOTT, M.F., WEBB, R.L. & REIDY, M.A. (1991). Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonism. Effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am. J. Pathol., 139, 1291-1296.
31. RODBARD, D. (1984). Lessons from the computerization of radioimmunoassays: an introduction to basic principles of modelling. In Computer in Endocrinology, ed. Rodbard D. & Forti, G. pp. 75-100. New York: Raven Press.
32. SACHINIDIS, A , KO, Y., WEISSER, P., MEYER ZU BRICKWEDDE, M.K., DÜSING, R., CHRISTIAN, R., WIECZOREK, A.J. & VETTER, H. (1993). EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells. J. Hypertens., 11, 155-162.
33. SASAKI, K., YAMANO, Y., BARDHAN, S., IWAI, N., MURRAY, J.J., HASEGAWA, M., MATSUDA, Y. & INAGAMI, T. (1991). Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature, 351, 230-233.
34. ULLIAN, M.E. & LINAS, S.L. (1990). Angiotensin II surface receptor coupling to inositol triphosphate formation in vascular smooth muscle cells. J. Biol. Chem., 265, 195-200.
35. WEBER, H., TAYLOR, D.S. & MOLLOY, C.J. (1994). Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells - Correlation with the expression of specific endogenous growth factors and reversal by Suramin. J. Clin. Invest., 93, 788-798.